Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
复制标题
DOI：
10.3389/fimmu.2018.01717
复制
发表时间：
2018
影响因子：
7.3
通讯作者：
Esmaeilzadeh A
中科院分区：
文献类型：
--
作者：
Elahi R;Khosh E;Tahmasebi S;Esmaeilzadeh A
配备嵌合抗原受体的T细胞（CAR T细胞）最近作为癌症治疗的新型免疫方法提供了有希望的进展。CAR T细胞疗法已经显示出惊人的结果，特别是在B细胞恶性肿瘤中;然而，它对实体瘤的成功率较低，这更应该与肿瘤微环境的特定特征有关。在这篇综述中，我们讨论了CAR的结构，已完成和正在进行的试验的当前临床优势，不良反应，挑战和争议，CAR的新工程方法，以及与血液恶性肿瘤和实体瘤中的CAR T细胞治疗相关的临床考虑。此外，我们还提供了最近引入的用于设计更智能的CAR T细胞模型的修改的全面描述。本文介绍了限制CAR T细胞最佳功能的具体障碍和问题，特别是在实体瘤上，以及根据CAR T细胞的新修饰和世代的可能解决方案。我们还提供了关于如何增强工程化下一代更智能的CAR T细胞的未来方向的信息，以减少不良反应并提高CAR T细胞对抗癌症的效力和功效。
T cells equipped with chimeric antigen receptors (CAR T cells) have recently provided promising advances as a novel immunotherapeutic approach for cancer treatment. CAR T cell therapy has shown stunning results especially in B-cell malignancies; however, it has shown less success against solid tumors, which is more supposed to be related to the specific characteristics of the tumor microenvironment. In this review, we discuss the structure of the CAR, current clinical advantages from finished and ongoing trials, adverse effects, challenges and controversies, new engineering methods of CAR, and clinical considerations that are associated with CAR T cell therapy both in hematological malignancies and solid tumors. Also, we provide a comprehensive description of recently introduced modifications for designing smarter models of CAR T cells. Specific hurdles and problems that limit the optimal function of CAR T cells, especially on solid tumors, and possible solutions according to new modifications and generations of CAR T cells have been introduced here. We also provide information of the future directions on how to enhance engineering the next smarter generations of CAR T cells in order to decrease the adverse effects and increase the potency and efficacy of CAR T cells against cancer.
登录
查看更多内容
影响因子：
17.1
作者：
Fedorov VD;Themeli M;Sadelain M
通讯作者：
Sadelain M
影响因子：
45.3
作者：
Ahmed, Nabil;Brawley, Vita S.;Gottschalk, Stephen
通讯作者：
Gottschalk, Stephen
表达 CD19 嵌合抗原受体的自体或供体来源的 T 细胞在患有髓外白血病的成人 B-ALL 中的耐受性和疗效。
影响因子：
7.2
作者：
Dai H;Zhang W;Li X;Han Q;Guo Y;Zhang Y;Wang Y;Wang C;Shi F;Zhang Y;Chen M;Feng K;Wang Q;Zhu H;Fu X;Li S;Han W
通讯作者：
Han W
影响因子：
11.2
作者：
Davies JK;Singh H;Huls H;Yuk D;Lee DA;Kebriaei P;Champlin RE;Nadler LM;Guinan EC;Cooper LJ
通讯作者：
Cooper LJ
DOI：
10.1038/mto.2016.11
发表时间：
2016
期刊：
Molecular therapy oncolytics
影响因子：
--
作者：
通讯作者：
--